Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment.

Viruses - 29 Jul 2022

Shah Rajiv, Barclay Stephen T, Peters Erica S, Fox Ray, Gunson Rory, Bradley-Stewart Amanda, Shepherd Samantha J, MacLean Alasdair, Tong Lily, van Vliet Vera Jannie Elisabeth, Ngan Chiu Bong Michael, Filipe Ana, Thomson Emma C, Davis Chris

Abstract excerpt

Direct-acting antivirals (DAAs) have revolutionised the treatment of Hepatitis C virus (HCV), allowing the World Health Organisation (WHO) to set a target of eliminating HCV by 2030. In this study we aimed to investigate glecaprevir and pibrentasvir (GP) treatment outcomes in a cohort of patients with genotype 2a infection. METHODS: Clinical data and plasma samples were collected in NHS Greater Glasgow & Clyde....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoisobutyric Acids
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Lactams, Macrocyclic

Share to Pyrrolidines

Share to Quinoxalines

Share to Scotland

Share to Substance Abuse, Intravenous

Source

Open in PubMed Open full text

Identifiers

PMID: 36016300
DOI: 10.3390/v14081678
PMCID: PMC9416734

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment.PMID 36016300Read ↗

Identification of 2 Novel Subtypes of Hepatitis C Virus Genotype 8 and a Potential New Genotype Successfully Treated With Direct Acting Antivirals.Semantic proximity Read ↗

Transmission Networks of HCV Genotype 1a Enriched With Pre-existing Polymorphism Q80K Among HIV-Infected Patients With Acute Hepatitis C in Poland.Semantic proximity Read ↗

Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study.Semantic proximity Read ↗

Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort.Semantic proximity Read ↗

Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis CSemantic proximity Read ↗

Prevalence of circulating hepatitis C virus genotypes and drug-resistant variants in former Soviet Union countries: A scoping review with genotype meta-analysis.Semantic proximity Read ↗

Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.Semantic proximity Read ↗

Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes.Semantic proximity Read ↗

Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.Semantic proximity Read ↗

Diagnosis of hepatitis C virus genotype 2k/1b needs NS5B sequencing.Semantic proximity Read ↗

Assessing hepatitis C virus distribution among vulnerable populations in London using whole genome sequencing: results from the TB-REACH studySemantic proximity Read ↗

A European single centre experience of management of hepatitis C virus genotype 4 infection with pegylated-interferon and ribavirin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.